NCT05921058 is a Phase 1, PHASE2 clinical trial of Secretome in Lupus Erythematosus, sponsored by Universitas Sebelas Maret.

Who is sponsoring NCT05921058?

NCT05921058 is sponsored by Universitas Sebelas Maret.

What drugs are being tested in NCT05921058?

Interventions in NCT05921058: Secretome, Placebo.

What condition does NCT05921058 study?

NCT05921058 studies Lupus Erythematosus.

Is NCT05921058 still recruiting?

NCT05921058 is currently completed. Last updated 27 June 2023.

Last reviewed 2023-06-27 · How we verify

NCT05921058

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of Mesenchymal Stem Cell Secretome in Lupus Patients

Completed Phase 1, PHASE2 Last updated 27 June 2023

What this trial tests

Phase 1, PHASE2 trial testing Secretome in Lupus Erythematosus in 15 participants. Completed in 9 March 2023.

Timeline

1 August 2022

Primary endpoint
30 December 2022

9 March 2023

Quick facts

Lead sponsor	Universitas Sebelas Maret
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	15
Start date	1 August 2022
Primary completion	30 December 2022
Estimated completion	9 March 2023
Sites	1 location across Indonesia

Drugs / interventions tested

Secretome — full drug profile →
Placebo

Conditions studied

Lupus Erythematosus — all drugs for Lupus Erythematosus →

Sponsor

Universitas Sebelas Maret — full company profile →

Who can join

Adults 18 to 60, any sex, with Lupus Erythematosus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research is a clinical trial of administering mesenchymal stem cell secretome to lupus patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Umbilical Cord Mesenchymal Stem Cell Secretome: A Potential Regulator of B Cells in Systemic Lupus Erythematosus.
Yordanova A, Ivanova M, Tumangelova-Yuzeir K, Angelov A, et al · · 2024 · cited 2× · PMID 39684227 · DOI 10.3390/ijms252312515
Umbilical cord mesenchymal stem cell-derived secretome as a potential treatment for systemic lupus erythematosus: A double-blind randomized controlled trial.
Nurudhin A, Werdiningsih Y, Sunarso I, Marwanta S, et al · · 2025 · cited 1× · PMID 40352183 · DOI 10.52225/narra.v5i1.1799
Enhancing Wound Healing Through Secretome-Loaded 3D-Printed Biomaterials.
Rattanachot T, Lokanathan Y, Fauzi MB, Maarof M. · · 2025 · PMID 40710638 · DOI 10.3390/gels11070476

Verify or expand the search:

Other trials of Secretome

Trials testing the same drug.

NCT07429253 — Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients · Phase 1, PHASE2 · recruiting
NCT06925386 — The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatment · Phase 2 · not yet recruiting
NCT06638970 — Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Drug Resistant Epilepsy Single Ce · Phase 1 · not yet recruiting
NCT06629909 — Safety and Feasibility of Human Umbilical Cord Mesenchymal Stem Cell-Derived Secretome in the Treatment of Liver Cirrhos · Phase 1 · not yet recruiting
NCT05777213 — Potential Injection of Human Umbilical Cord Secretome in the Case of Trophic Ulcers (Pre-post Intervention) · Phase 1 · completed

Other recruiting trials for Lupus Erythematosus

Currently open trials in the same condition.

NCT06426316 — The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology. · NA · recruiting
NCT05251415 — Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases · recruiting

Other Universitas Sebelas Maret trials

Trials by the same sponsor.

NCT07475065 — The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy · Phase 2, PHASE3 · not yet recruiting
NCT07039682 — Empowering Knowledge, Self-Testing & Resilience Through Innovative Methods for HIV · NA · not yet recruiting
NCT07380178 — The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis · NA · completed
NCT06871358 — The Effect of Atorvastatin 80 mg on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in PCI-STEMI Patients · NA · completed
NCT07121569 — Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05921058 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitas Sebelas Maret
Last refreshed: 27 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05921058.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing